Literature DB >> 17239317

Therapeutic options in advanced prostate cancer: present and future.

Richard D Sowery, Alan I So, Martin E Gleave.   

Abstract

Patients with advanced prostate cancer now have many treatment options available including first- and second-line hormonal therapy, radiotherapy, bisphosphonate therapy with zoledronic acid, and taxane-based chemotherapy. These options now give clinicians an opportunity to offer their patients symptomatic relief and most importantly improve overall survival. This article reviews the current treatment options available for men with advanced prostate cancer. In addition, novel treatment options under development, including calcitriol, immunotherapies, small molecule inhibitors, and nucleotide-based targeted therapy, are discussed.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17239317     DOI： 10.1007/s11934-007-0021-9

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


  31 in total

Review 1.  Radiation therapy and radio-nuclides for palliation of bone pain.

Authors:  Juanita Crook
Journal:  Urol Clin North Am       Date:  2006-05       Impact factor: 2.241

Review 2.  Combined androgen blockade: an update.

Authors:  Laurence Klotz
Journal:  Urol Clin North Am       Date:  2006-05       Impact factor: 2.241

3.  A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.

Authors:  Amy M Lin; Brian I Rini; Vivian Weinberg; Kristen Fong; Charles J Ryan; Jonathan E Rosenberg; Lawrence Fong; Eric J Small
Journal:  BJU Int       Date:  2006-10       Impact factor: 5.588

4.  A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.

Authors:  Kim N Chi; Elizabeth Eisenhauer; Ladan Fazli; Edward C Jones; S Larry Goldenberg; Jean Powers; Dongsheng Tu; Martin E Gleave
Journal:  J Natl Cancer Inst       Date:  2005-09-07       Impact factor: 13.506

5.  Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin.

Authors:  Tobias Zellweger; Kim Chi; Hideaki Miyake; Hans Adomat; Satoshi Kiyama; Kirsten Skov; Martin E Gleave
Journal:  Clin Cancer Res       Date:  2002-10       Impact factor: 12.531

6.  Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.

Authors:  T Zellweger; H Miyake; S Cooper; K Chi; B S Conklin; B P Monia; M E Gleave
Journal:  J Pharmacol Exp Ther       Date:  2001-09       Impact factor: 4.030

7.  Bisphosphonate treatment inhibits the growth of prostate cancer cells.

Authors:  M V Lee; E M Fong; F R Singer; R S Guenette
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

8.  Importance of continued testicular suppression in hormone-refractory prostate cancer.

Authors:  C D Taylor; P Elson; D L Trump
Journal:  J Clin Oncol       Date:  1993-11       Impact factor: 44.544

9.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

10.  Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer.

Authors:  J Steinberg; R Oyasu; S Lang; S Sintich; A Rademaker; C Lee; J M Kozlowski; J A Sensibar
Journal:  Clin Cancer Res       Date:  1997-10       Impact factor: 12.531
View more
  11 in total

1.  Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer.

Authors:  Murali M Yallapu; Sheema Khan; Diane M Maher; Mara C Ebeling; Vasudha Sundram; Neeraj Chauhan; Aditya Ganju; Swathi Balakrishna; Brij K Gupta; Nadeem Zafar; Meena Jaggi; Subhash C Chauhan
Journal:  Biomaterials       Date:  2014-07-12       Impact factor: 12.479

2.  The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer.

Authors:  Hui Shen; Nathan Powers; Nitin Saini; Clay E S Comstock; Ankur Sharma; Katherine Weaver; Monica P Revelo; William Gerald; Erin Williams; Walter J Jessen; Bruce J Aronow; Gary Rosson; Bernard Weissman; Christian Muchardt; Moshe Yaniv; Karen E Knudsen
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

Review 3.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

Review 4.  Natural compounds with proteasome inhibitory activity for cancer prevention and treatment.

Authors:  H Yang; K R Landis-Piwowar; D Chen; V Milacic; Q P Dou
Journal:  Curr Protein Pept Sci       Date:  2008-06       Impact factor: 3.272

5.  Anticancer activity of bicalutamide-loaded PLGA nanoparticles in prostate cancers.

Authors:  Jun Guo; Shu-Hong Wu; Wei-Guo Ren; Xin-Li Wang; Ai-Qing Yang
Journal:  Exp Ther Med       Date:  2015-10-14       Impact factor: 2.447

6.  Delivery Of Curcumin Nanoliposomes Using Surface Modified With CD133 Aptamers For Prostate Cancer.

Authors:  Qi Ma; Wei Qian; Wei Tao; Yanling Zhou; Boxin Xue
Journal:  Drug Des Devel Ther       Date:  2019-11-28       Impact factor: 4.162

7.  Curcumin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells: molecular mechanisms of apoptosis, migration and angiogenesis.

Authors:  Sharmila Shankar; Qinghe Chen; Krishna Sarva; Imtiaz Siddiqui; Rakesh K Srivastava
Journal:  J Mol Signal       Date:  2007-10-04

8.  Highly Stable PEGylated Poly(lactic-co-glycolic acid) (PLGA) Nanoparticles for the Effective Delivery of Docetaxel in Prostate Cancers.

Authors:  Long-Bin Cao; Sha Zeng; Wei Zhao
Journal:  Nanoscale Res Lett       Date:  2016-06-21       Impact factor: 4.703

9.  MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.

Authors:  Wenqing Qi; Larry S Cooke; Amy Stejskal; Christopher Riley; Kimiko Della Croce; Jose W Saldanha; David Bearss; Daruka Mahadevan
Journal:  BMC Cancer       Date:  2009-05-11       Impact factor: 4.430

Review 10.  AR, the cell cycle, and prostate cancer.

Authors:  Steven P Balk; Karen E Knudsen
Journal:  Nucl Recept Signal       Date:  2008-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.